Could a common diabetes drug shrink fatty livers in obese teens?

NCT ID NCT06355310

Recruiting now Disease control Sponsor: Justin Ryder Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether empagliflozin (Jardiance), a drug used for diabetes, can reduce liver fat in teenagers with obesity and non-alcoholic fatty liver disease (NAFLD). Forty participants aged 16 to under 21 will receive either the drug or a placebo for 26 weeks. The main goal is to see if liver fat decreases, along with other health markers like weight and liver enzymes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Empagliflozin (Jardiance)
What this could lead to: If it works, this could point toward a new treatment option for teenagers with fatty liver disease, potentially reducing liver fat and improving metabolic health.
What could go wrong: This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. The drug is already approved for diabetes, but its safety and effectiveness for this specific condition in teens are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC FATTY LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC FATTY LIVER DISEASE

Contacts and locations

Locations

Ann & Robert H Lurie Children's Hospital of Chicago
RECRUITING

Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.